Zealand Pharma A/S ZLDPF
34.63 USD +1.55 (+4.68%)
At closeNov 3, 2026, 4:00 PM EST
34.50 Day range 34.50
33.08 52-week range 83.12
- YTD
- -51.64%
- 1 year
- -53.76%
- Market cap
- 2.30B
- EPS (ttm)
- 6.03
- P/E ratio
- 5.74
- YTD return
- -51.64%
- 1-year return
- -53.76%
- Volume
- 100
- Avg volume
- 537
- Open
- 34.50
- Previous close
- 33.08
- Day's range
- 34.50 – 34.50
- 52-week range
- 33.08 – 83.12
- Earnings date
- Aug 13, 2026
2Y -88.86 (-71.96%)
Next earnings
Aug 13, 2026
Expected Aug 13, 2026. Consensus EPS estimate 0.1431.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jun 30, 2026 | 0.1431 | — | — | — |
| May 7, 2026 | Mar 31, 2026 | -1.37 | -0.87 | +0.50 | +36.27% |
| Feb 19, 2026 | Dec 31, 2025 | -1.26 | -0.81 | +0.45 | +35.60% |
| Nov 13, 2025 | Sep 30, 2025 | -1.11 | -0.90 | +0.21 | +18.92% |
| Aug 14, 2025 | Jun 30, 2025 | 17.22 | 16.06 | -1.16 | -6.74% |
| May 8, 2025 | Mar 31, 2025 | -0.77 | -0.67 | +0.10 | +12.99% |
News
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low – Time to Sell? 
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell? 
Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Hold” from Brokerages 
Zealand Pharma's short bowel syndrome drug wins backing from EU panel 
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates 
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model 
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker 
Drugmakers race to find a place in the next wave of obesity drugs 
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects 
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Your note
Sign in to keep a note on ZLDPF — it syncs with the Stock Master app.